Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
02 avr. 2024 07h30 HE
|
Annovis Bio Inc.
MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative...
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
01 avr. 2024 08h00 HE
|
Annovis Bio Inc.
Further look at earlier Phase 1b study by ADCS unveils confirmatory data MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company...
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
20 mars 2024 07h30 HE
|
Annovis Bio Inc.
MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced...
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
27 févr. 2024 08h00 HE
|
Annovis Bio Inc.
MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel...
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
14 févr. 2024 07h30 HE
|
Annovis Bio Inc.
MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last...
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio
30 janv. 2024 08h00 HE
|
Annovis Bio Inc.
MALVERN, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the filing...
Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
24 janv. 2024 08h00 HE
|
Annovis Bio Inc.
MALVERN, Pa., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, has announced a...
Annovis Bio to Participate in the 139th Yale CEO Summit
11 déc. 2023 13h00 HE
|
Annovis Bio Inc.
BERWYN, Pa., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s...
Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease
05 déc. 2023 07h30 HE
|
Annovis Bio Inc.
BERWYN, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last...
Annovis Bio Appoints Andrew Walsh as Vice President Finance
01 déc. 2023 07h30 HE
|
Annovis Bio Inc.
BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s...